|
|
News Breaks | | | | March 1, 2013 | | 14:37 EDT |  | BMY, SHPG, BIIB | Bristol-Myers continues to explore acquisitions, DJ reports
Bristol-Myers (BMY) has considered deals for Biogen Idec (BIIB) and Shire (SHPG), according to Dow Jones. | |
|
News For BMY;BIIB;SHPG From The Last 14 Days Check below for free stories on BMY;BIIB;SHPG the last two weeks. |
|
|
| June 19, 2013 | | 05:43 EDT | | BMY | AstraZeneca, Bristol-Myers announce top line results of Phase 4 trial of Onglyza
 Subscribe for More Information | | | June 18, 2013 | | 07:22 EDT |  | SHPG | Citigroup to host a conference
Subscribe for More Information | | | June 17, 2013 | | 11:55 EDT |  | SHPG | High option volume stocks: SPHG CSIQ TS GAME CRZO
Subscribe for More Information | | | 08:54 EDT |  | BIIB | Biogen weekly MS drug scripts up 39%, says Citigroup
Subscribe for More Information | | | 07:28 EDT | | BMY | Cambridge Healthtech Institute to host a conference
Subscribe for More Information | | | 07:25 EDT | | SHPG | Leerink to host a conference
Subscribe for More Information | | | June 14, 2013 | | 09:03 EDT | | BMY | Bristol-Myers, AstraZeneca to present 33 abstracts at ADA Scientific Sessions
AstraZeneca (AZN) and Bristol-Myers Squibb (BMY) announced that 33 abstracts on the companies’ research in diabetes have been accepted for presentation at the 73rd Scientific Sessions of the American Diabetes Association in Chicago, June 21-25. The data include studies from five marketed products as well as dapagliflozin, an investigational compound in the U.S., currently approved for use in the European Union, Australia, New Zealand and Mexico. Key presentations include: the first presentation of Phase IIa pilot data exploring the use of dapagliflozin in adult patients with type 1 diabetes; four-year data examining the durability of dapagliflozin vs. glipizide as add-on therapies in patients with type 2 diabetes inadequately controlled on metformin; study evaluating the efficacy and tolerability of saxagliptin in patients with type 2 diabetes and a history of cardiovascular disease; three-year data from a study examining the effect of exenatide once weekly on sustained glycemic control and weight compared with insulin glargine; and Phase IV study examining glycemic control, weight, and hypoglycemia with exenatide compared to mealtime administration of rapid-acting analog insulin. | | | 08:02 EDT | | BMY | Bristol-Myers, Simcere enter Orencia pact for China
Subscribe for More Information | | | June 13, 2013 | | 11:02 EDT | | BMY | Leerink's major pharma analyst holds an analyst/Industry conference call
Subscribe for More Information | | | June 12, 2013 | | 16:20 EDT |  | BIIB | On The Fly: Closing Wrap
Stocks on Wall Street were lower despite opening sharply higher as the market looked to avoid its first three day losing streak of the year. Downside momentum quickly took hold however, and the averages moved steadily lower through the session, moving to their lows in the final hour of trading but finishing just off those levels. ECONOMIC EVENTS: In the U.S., the MBA's purchase applications composite index rose 5.0% for the week. The U.S. posted a $139B May budget deficit against expectations for a $130B deficit, and compared to a $124.6B deficit a year ago. In Europe, factory production in the 17-nation euro area rose 0.4% in April from March, compared to expectations for it to remain unchanged. COMPANY NEWS: Cooper Tire (CTB) agreed to be acquired by India's Apollo Tyres for $35.00 per share in cash, or $2.5B. Cooper shares surged $10.10, or 41.12%, to $34.66 to trade near $34.50 following the deal announcement, while peer Goodyear Tire (GT) advanced about 33c, or 2.26%, to $14.93... Live Nation (LYV) shares gained $2.33, or 16.84%, to $16.17 after the company announced it prevailed in an arbitration ruling related to a ticketing license software agreement... MAJOR MOVERS: Among the notable gainers was Ulta Salon (ULTA), up $12.51, or 14.87%, to $96.64 following its quarterly earnings report. Also higher was Health Management (HMA), up $1.58, or 11.34%, to $15.51 after Glenview Capital said in a filing it is seeking to repeal a provision that prevents entities from holding more than 15% of the company's stock and saying it would look to nominate candidates to the company's board. Among noteworthy losers was Biogen (BIIB), down $16.48, or 7.39%, to $206.55 after the stock was downgraded to Neutral from Buy at Citigroup, which cited concerns that EU medical regulators are unlikely to approve the company's multiple sclerosis treatment. Also lower were U.S.-listed shares of Vodafone (VOD), down 71c, or 2.47%, to $28.12 after the company confirmed it approached Kabel Deutschland about a possible deal. INDICES: The Dow was down 126.79, or 0.84%, to 14,995.23; the S&P 500 was down 13.61, or 0.84%, to 1,612.52; the Nasdaq was down 36.52, or 1.06%, to 3,400.43. | | | | 13:15 EDT | | BMY | Bristol-Myers, AstraZeneca issue statement on review of some therapies
Subscribe for More Information | | | 10:31 EDT | | BIIB | Biogen retreats after analyst cuts rating to Neutral
Subscribe for More Information | | | 10:14 EDT |  | BIIB | On the Fly: Downgrade Summary
Subscribe for More Information | | | 07:38 EDT | | BIIB | Biogen price target raised to $268 from $219 at Brean Capital
Subscribe for More Information | | | 06:01 EDT | | BIIB | Biogen downgraded to Neutral from Buy at Citigroup
Subscribe for More Information | | | June 11, 2013 | | 18:09 EDT | | BMY | Orencia trial data shows efficacy rate comparable to Humira
Bristol-Myers announced the results of year two data from AMPLE, a trial of 646 patients comparing the subcutaneous formulation of Orencia, or abatacept, vs. Humira, or adalimumab, each on a background of MTX, in biologic naïve patients with moderate to severe RA. The AMPLE year two data are being presented this week at the European League Against Rheumatism annual congress and highlighted during a congress press conference. AMPLE met its primary endpoint as measured by non-inferiority of ACR20 at year one. The Orenica regimen achieved comparable rates of efficacy vs. the Humira regimen, or 64.8% vs. 63.4%, respectively. Onset of response was also generally similar for the two groups. Year two of the study remained investigator-blinded. At year two, the Orencia regimen achieved the same rate of efficacy as the Humira regimen based on ACR20. | | | 11:47 EDT | | BIIB | Deutsche Bank's biotech analyst holds an analyst/industry conference call
Biotech Analyst Karnauskas discusses Biogen's (BIIB) treatment for Multiple Sclerosis, Tecfidera, as well as reviewing IMS Tecfidera data, on an Analyst/Industry conference call to be held on June 11 at 3 pm. | | | 08:01 EDT | | BMY | Leerink's major pharma and biotech analysts hold a conference call
Subscribe for More Information | | | June 10, 2013 | | 07:40 EDT | | BIIB | Leerink's biotech analyst holds analyst/industry conference call on ASCO
Subscribe for More Information | | | 07:10 EDT | | SHPG | Shire price target raised to $115 from $101-$102 at Leerink
Subscribe for More Information | | |
|
|
|
|
|
|
